A Wilcoxon test indicated that there were no significant differences (P > 0.05) in CSF amyloid-β A4 protein levels between APOE ε4 carriers and noncarriers with AD, PD or nonimpaired controls (Extended Data Fig. 1b). This evidence concerns the gene APOE and Parkinson disease.